Open access peer-reviewed chapter

Ubiquitin-Independent Proteasomal Degradation Mediated by Antizyme

Written By

Noriyuki Murai

Submitted: 01 April 2020 Reviewed: 22 April 2020 Published: 04 June 2020

DOI: 10.5772/intechopen.92623

From the Edited Volume

Ubiquitin - Proteasome Pathway

Edited by Xianquan Zhan

Chapter metrics overview

881 Chapter Downloads

View Full Metrics


Most of the proteins in eukaryotic cells are degraded by the proteasome in an ubiquitin-dependent manner. However, ubiquitin-independent protein degradation pathway by the 26S proteasome exists in the cells. Ornithine decarboxylase (ODC) is a well-known protein that is degraded by the 26S proteasome without ubiquitination. Degradation of ODC requires the protein, “antizyme (AZ),” that is induced by polyamine and binds to the ODC monomer to inhibit ODC activity and target it to the 26S proteasome for proteolytic degradation. Namely, AZ contributes the feedback regulation of intracellular polyamine level. ODC has been considered to be the only protein that AZ binds and accelerates its degradation. However, recently AZ-mediated proteasomal protein degradation will gradually increase. Most recently, we found that one of the antizyme families, AZ2, accelerates c-Myc degradation by the proteasome without ubiquitination. In this chapter, we introduce latest several ubiquitin-independent proteasomal degradation mediated by antizyme.


  • antizyme
  • ubiquitin-independent degradation
  • ornithine decarboxylase
  • 26S proteasome
  • polyamines
  • c-Myc

1. Introduction

In eukaryotic cells, intracellular protein degradation is mainly regulated by the ubiquitin-proteasome system, where abnormal and unwanted proteins are targeted by polyubiquitin, which is produced from monoubiquitin by ubiquitin-activating enzyme (E1) and ubiquitin-conjugating enzyme (E2) [1]. The proteins that conjugated polyubiquitin by ubiquitin ligase (E3) are finally targeted to the 26S proteasome [2]. However, there is accumulating evidence that ubiquitin-independent proteasomal protein degradation pathway exists in the cells [3, 4]. Although ubiquitin-dependent proteasomal protein degradation is carried out normally by 26S proteasome, there are many reports that ubiquitin-independent proteasomal protein degradations are executed by the only 20S proteasome without the energy of ATP hydrolysis [4]. Among others, some ubiquitin-independent degradation pathways are known to be carried out using not the 20S but the 26S proteasome with the energy of ATP hydrolysis. In this chapter, we introduce ubiquitin-independent proteasomal degradation pathway mediated by polyamine regulating protein, “antizyme.”


2. What is antizyme?

Polyamines are highly charged bioactive substances presented ubiquitously in species from bacteria to human. Polyamines are necessary for cell growth and are involved in highly diversified cellular functions such as cell division, apoptosis, autophagy, oxidative stress, and ion channel activity. There are three major polyamines, putrescine, spermidine, and spermine, in the cells [5, 6]. Intracellular polyamine concentration is highly regulated by the protein “antizyme” [7, 8, 9, 10] that is widely distributed from yeast to human [11]. Antizyme (AZ) is induced in response to the increased concentration of intracellular polyamines through the polyamine-induced translational frameshifting mechanism [12]. AZ mRNA consists of two ORFs (ORF1 and ORF2). In the low polyamine concentration, translation of ORF1 is terminated at stop codon “UGA” of ORF1, and short product is produced (Figure 1). But in the increasing cellular polyamine concentration, reading frame shifts +1 direction at the end of ORF1 (Figure 1 bottom column). In this case, following ORF1, ORF2 is translated and full length active product “antizyme” is produced [12, 13]. The induced AZ protein binds to ornithine decarboxylase (ODC) monomer, a key enzyme in polyamine biosynthesis, and catalyzes the conversion from ornithine to putrescine and inhibits its activity. AZ-bound ODC is targeted to the 26S proteasome for degradation without ubiquitination (Figure 1) [14]. AZ also suppresses polyamine uptake by inhibiting membrane polyamine transporter (Figure 1) [15, 16]. Thus, AZ provides the negative feedback regulation of cellular polyamines. In addition, AZ is regulated by the protein, antizyme inhibitor (AZIN), that is homologous to ODC and can bind to AZ with higher affinity than ODC but lacking the enzymatic activity [17, 18].

Figure 1.

Negative feedback regulation of cellular polyamine by antizyme. Three cis-acting elements, UGA stop codon, upstream stimulator, and pseudoknot structure, are known to be important for +1 frameshifting (bottom column). Putrescine, spermidine, and spermine are major polyamines in the mammalian cell. Putrescine synthesized from ornithine by ODC could be metabolized to spermidine and spermine in the cells. PAT is a polyamine transporter that uptakes polyamines from outside of the cells.

In mammals, cells express three members of AZ protein family, AZ1–3 (Table 1) [19]. AZ1 and AZ2 are distributed ubiquitously in most of the tissues, whereas AZ3 is testis specific [20, 21, 22]. Both AZ1 and AZ2 bind to ODC and accelerate its degradation in the cells [9, 23], but AZ3 has no activity for acceleration of ODC degradation [24]. The rate of ODC degradation by AZ1 is faster than that by AZ2 [23, 25]. Polyamine (putrescine) concentration of AZ1 knockdown cells is markedly increased, compared to that of AZ2 knockdown and control cells [26]. Therefore, it is thought that AZ1 mainly regulates cellular polyamine concentration. On the other hand, although AZ2 is highly homologous to AZ1 [25], it is considered that AZ2 is not a backup of AZ1 because of some differences between each other. AZ2 was found as one of the genes upregulated in neuronal cells by the drug that induces seizure [27]. Nucleic acid sequence of AZ2 is evolutionally conserved higher than that of AZ1 [11]. AZ2 is localized mainly in the nucleus [26] and is phosphorylated in the cells [28]. We will mention about AZ2 specific function with its interacting protein that we found very recently in this chapter.

Table 1.

Characteristics of antizyme family.


3. Antizyme-interacting proteins and ubiquitin-independent proteasomal degradation

3.1 Antizyme 1-interacting proteins

It had been considered that ODC is the only protein degraded through AZ-mediated ubiquitin-independent proteasomal degradation system. However, recently several AZ1-interacting proteins other than ODC have been reported (Table 2). Although it has already been reported that those proteins are degraded by the ubiquitin-proteasome pathway, AZ1 could also accelerate those degradation without ubiquitination (Tables 1 and 2, Figure 1). Smad1, which is involved in bone morphogenetic protein (BMP) signaling pathway [29, 30], is the first reported protein that interacts AZ1 other than ODC [31]. In this case, newly synthesized HsN3, which is β-subunit for 20S proteasome, forms ternary complex with AZ1 and smad1. This complex may bind to 20S proteasome, and next 19S complex is docked on 20S, and then smad1 is degraded by the 26S proteasome.

Table 2.

The proteins degraded by antizyme-mediated ubiquitin-independent proteasomal pathway.

Newman et al. reported that AZ1 has the ability to accelerate the degradation of cyclin D1, one of the cell cycle regulatory protein families [32]. Cyclin D1 interacts with cyclin-dependent kinase (CDK), and accumulation of cyclin D1-CDK complex is important for cell cycle progression [33]. This protein is already known to be degraded by ubiquitin-proteasome pathway [34]. They demonstrated that AZ1 induction by polyamine or overexpression of AZ1 accelerates cyclin D1 degradation, and knockdown of AZ1 suppresses it. Furthermore, in vitro experiment using purified cyclin D1, AZ1, and rabbit reticulocyte extracts as a source of 26S proteasome, AZ1 accelerated cyclin D1 degradation in a ATP-dependent manner. AZ1 could also degrade ubiquitin-deficient mutant of cyclin D1 in the cells [32]. In vitro size distribution analysis for binding between AZ1, cyclin D1, and ODC suggested that binding sites of AZ1 for cyclin D1 and ODC do not overlap each other, and cyclin D1 binds to the N-terminus of AZ1 and ODC binds at the C-terminus, respectively. Binding affinity of AZ1 to cyclin D1 is fourfold lower than that to ODC [35]. Although physiological significance is not clear, it showed that those three proteins form cyclin D1-AZ1-ODC ternary complex.

The oncogene Aurora A encodes a protein kinase that exerts essential roles in mitotic events and is important for induction of centrosome amplification [36]. Overexpression of Aurora A in many cancers induces aneuploidy, centrosome anomaly, poor prognosis, and invasiveness [37, 38]. Aurora A is ubiquitinated by the E3 ubiquitin (Ub) ligase, anaphase-promoting complex/cyclosome (APC/C) that is activated by both cell-division cycle protein 20 (Cdc20) and Cdh1, substrate-recognition subunit of APC/C, and is degraded by the proteasome [3940]. However, Lim and Gopalan demonstrated that AZ1 could accelerate Aurora A degradation with ubiquitin-independent manner, where Aurora A kinase-interacting protein 1 (AURKAIP1), a negative regulator of Aurora A, enhances the binding of AZ1 to Aurora A and facilitates the recognition of Aurora A by the proteasome [41].

Mps1 is protein kinase required for centrosome duplication in regulating the spindle assembly checkpoint [42, 43]. Accumulation of Mps1 at the centrosome causes aberrant centriole assembly [44, 45]. In fact in various tumor cells, centrosomal Mps1 pool is increased, which causes abnormal centrosome duplication [44]. Thus degradation of Mps1 is important for proper pool of Mps1 at the centrosome. Although degradation of Mps1 is known to be mediated by the proteasome, amino acid residue 420–507 of the human Mps1 that is sufficient for its degradation does not contain APC/C recognition motifs, suggesting the commitment of Mps1 to ubiquitin-independent proteasomal degradation [45]. Kasbek et al. reported that AZ1 localizes to the centrosomes and binds to Mps1 to control the levels of centrosomal Mps1 by accelerating the degradation of Mps1 [46]. Fluorescent microscopy analysis showed that centrosomal Mps1 level is dependent on AZ1 expression, overexpression of AZ1 decreases the centrosome Mps1 level, and conversely, AZ1 knockdown by siRNA increases that. Furthermore, deletion of degradation signal of Mps1 abolished the regulation of centrosomal Mps1 level by AZ1. In addition, overexpressing AZIN in the cells to trap AZ1 and inhibit its function increased centrosomal Mps1 level. Thus the balance of AZ1 and Mps1 level in the centrosome is important for the centrosome duplication process.

P73 is a homolog of p53 and exists as two major forms, TAp73 or Delta-N (DN) p73. TAp73 is full-length form and exerts proapoptotic function, whereas DNp73, which is amino-terminal transactivation domain lacking the form of p73, exhibits dominant-negative inhibitor activity for both p73 and p53, resulting in antiapoptotic properties [47]. Therefore, in the stress condition like DNA damage, reduction of DNp73 level is needed to execute apoptosis [48, 49, 50]. It is known that degradation of both TAp73 and DNp73 is mediated by E3-ubiquitin ligase Itch in a proteasome-dependent manner in normal condition [51]. However, in Itch-decreased condition such as DNA damage by UV irradiation, stabilization of TAp73 was observed, but DNp73 was not [51]. Therefore, it was considered that the degradation of TAp73 and DNp73 is regulated by different mechanisms. Dulloo et al. reported that reduction of DNp73 in the stress condition is due to the degradation of DNp73 by AZ1-mediated ubiquitin-independent proteasomal pathway [52]. They showed that degradation of DNp73 could be induced by genotoxic stresses such as UV irradiation and doxorubicin treatment. Inhibition of ubiquitin-activating enzyme E1 by the inhibitor PYR41 could not block DNp73 degradation, indicating that it relies on ubiquitin-independent pathway. They demonstrated that polyamine induced AZ1 to bind to DNp73 for accelerating its degradation. Interestingly, AZ1-mediated DNp73 degradation is dependent on transcription factor c-Jun that is activated by stress signals. Overexpression and knocking down of AZ1 also showed that even in the presence of c-Jun, AZ1 is necessary for genotoxic stress to induce DNp73 degradation. Although it is not clear how c-Jun operates AZ1 expression, c-Jun may act upstream of polyamine biosynthesis pathway.

Thus, several proteins degraded by AZ1-mediated proteasome pathway are found, but AZ2-interacting protein or AZ2-mediated proteasomal degradation other than ODC has not been reported. We recently found two AZ2-interacting proteins, and one of the two was the protein that accelerated its proteasomal degradation by AZ2 without ubiquitination (see next section).

3.2 Antizyme 2-interacting proteins

As mentioned above, AZ2 also binds to ODC and accelerates its degradation in the cells [9]. However, we have considered that AZ2 has specific function other than AZ1 because of the differences such as nuclear localization [26, 28], highly gene conservation between species [20], and high expression in neuronal cells [53]. We performed comprehensive analysis of AZ2-interacting protein using two-hybrid technique. Two AZ2-interacting proteins were identified. One is ATP citrate lyase (ACLY), which is the enzyme catalyzing acetyl-CoA production in cytosol [54] and related to lipid anabolism and acetylation of cellular components [55]. We found that ACLY binds not only to AZ2 but also to AZ1 by immunoprecipitation assay [56]. Degradation assay for ACLY was performed in expectation of ubiquitin-independent proteasomal degradation. However, AZs have no ability to accelerate ACLY degradation. Surprisingly, AZ1 and AZ2 activate catalytic activity of ACLY [56]. The other is proto-oncogene c-Myc that is a transcription factor with a basic region/helix–loop–helix/leucine zipper domain and forms heterodimer with Max for DNA binding [57, 58]. c-Myc functions as a master regulator of a variety of cellular processes such as cell growth, differentiation, survival, and apoptosis [58]. In cell growth, c-Myc targets ODC gene [59] and promotes synthesis of polyamine that is important for stabilization of nucleic acids, transcription, translation, and +1 frameshifting on AZ mRNA [6].

It is known that degradation of c-Myc is mediated by ubiquitin-proteasome pathway, where c-Myc is phosphorylated at Thr-58 (pT58) and Ser-62 (pS62) by extracellular signal-regulated kinase, ERK, and glycogen synthase kinase 3β, GSK-3β, respectively [60, 61]. After dephosphorylation at Ser-62 by protein phosphatase 2A, PP2A, pT58-c-Myc is ubiquitinated by E3-ubiquitin ligase Fbxw7 for proteasomal degradation [60, 62]. At first, AZ2-interacting protein identified by the comprehensive analysis mentioned above was not c-Myc but a protein that has basic region/helix–loop–helix/leucine zipper domain and interacts with c-Myc (Murai et al., manuscript in preparation). However, in the process of analyzing the interaction with AZ2, we found that AZ2 interacts with c-Myc in the cells by immunoprecipitation assay. Subcellular localization analysis of both proteins using fluorescent protein tags or antibody conjugated fluorescent probe revealed that AZ2 co-localized with c-Myc in the nucleus. Treatment of proteasome inhibitor MG132 changes the nuclear co-localization of both proteins to nucleolar co-localization [26]. Overexpression of AZ2 or addition of polyamine in the cells accelerated c-Myc degradation, and knockdown of AZ2 with siRNA suppressed it. Furthermore, E1 inhibitor PYR-41 could not suppress AZ2-mediated proteasomal c-Myc degradation [26]. These results suggest that AZ2-mediated ubiquitin-independent nucleolar c-Myc degradation pathway other than ubiquitin-dependent one exists in the cells (Figure 2).

Figure 2.

AZ2-mediated c-MYC degradation in the nucleolus. Two distinct c-Myc degradation pathways exist in the cells. It is thought that AZ2 pathway functions under the stress condition (polyamine increased condition) such as glucose-free and hypoxia.


4. Conclusions

In this chapter, antizyme-mediated ubiquitin-independent proteasomal degradation has been discussed. All the proteins mentioned above are already known as the proteins degraded by ubiquitin-proteasomal pathway. It is not clear how antizyme-mediated ubiquitin-independent degradation of these proteins is physiologically significant. Normally subcellular localization of ODC is mainly in the cytoplasm and at least not in the nucleolus even in the presence of MG132. In addition, ODC is necessary for cell growth, and the affinity of interaction between antizyme and ODC is high [63]; in such condition, ODC probably occupies almost all antizymes in the cytosol, and antizymes hardly function for other antizyme-interacting proteins [64]. In this context, because subcellular localization of both AZ2 and its interacting protein c-Myc is in the nucleus or nucleolus, cytosolic protein ODC could not interact with AZ2 there. ODC is one of the c-Myc-targeting proteins, and AZ2 may function upstream of c-Myc especially under the stress condition such as glucose free and hypoxic condition [26]. Further studies are needed to elucidate the significance of antizyme-proteasome degradation pathway.



This research was supported by the Jikei University Graduate Research Fund and JSPS KAKENHI Grant Number JP 19K08283.


  1. 1. Hershko A, Ciechanover A. The ubiquitin system. Annual Review of Biochemistry. 1998;67:425-479
  2. 2. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiological Reviews. 2002;82(2):373-428
  3. 3. Jariel-Encontre I, Bossis G, Piechaczyk M. Ubiquitin-independent degradation of proteins by the proteasome. Biochimica et Biophysica Acta. 2008;1786(2):153-177
  4. 4. Buneeva OA, Medvedev AE. Ubiquitin-independent protein degradation in proteasomes. Biomeditsinskaya Khimiya. 2018;64(2):134-148
  5. 5. Pegg AE, Casero RA Jr. Current status of the polyamine research field. Methods in Molecular Biology (Clifton, NJ). 2011;720:3-35
  6. 6. Casero RA Jr, Murray Stewart T, Pegg AE. Polyamine metabolism and cancer: Treatments, challenges and opportunities. Nature Reviews. Cancer. 2018;18(11):681-695
  7. 7. Hayashi S, Murakami Y, Matsufuji S. Ornithine decarboxylase antizyme: A novel type of regulatory protein. Trends in Biochemical Sciences. 1996;21(1):27-30
  8. 8. Li X, Coffino P. Regulated degradation of ornithine decarboxylase requires interaction with the polyamine-inducible protein antizyme. Molecular and Cellular Biology. 1992;12(8):3556-3562
  9. 9. Coffino P. Regulation of cellular polyamines by antizyme. Nature Reviews. Molecular Cell Biology. 2001;2(3):188-194
  10. 10. Heller JS, Fong WF, Canellakis ES. Induction of a protein inhibitor to ornithine decarboxylase by the end products of its reaction. Proceedings of the National Academy of Sciences of the United States of America. 1976;73(6):1858-1862
  11. 11. Ivanov IP, Gesteland RF, Atkins JF. Antizyme expression: A subversion of triplet decoding, which is remarkably conserved by evolution, is a sensor for an autoregulatory circuit. Nucleic Acids Research. 2000;28(17):3185-3196
  12. 12. Matsufuji S, Matsufuji T, Miyazaki Y, Murakami Y, Atkins JF, Gesteland RF, et al. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell. 1995;80(1):51-60
  13. 13. Atkins JF, Loughran G, Bhatt PR, Firth AE, Baranov PV. Ribosomal frameshifting and transcriptional slippage: From genetic steganography and cryptography to adventitious use. Nucleic Acids Research. 2016;44(15):7007-7078
  14. 14. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, et al. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature. 1992;360(6404):597-599
  15. 15. Mitchell JL, Judd GG, Bareyal-Leyser A, Ling SY. Feedback repression of polyamine transport is mediated by antizyme in mammalian tissue-culture cells. The Biochemical Journal. 1994;299(Pt 1):19-22
  16. 16. Suzuki T, He Y, Kashiwagi K, Murakami Y, Hayashi S, Igarashi K. Antizyme protects against abnormal accumulation and toxicity of polyamines in ornithine decarboxylase-overproducing cells. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(19):8930-8934
  17. 17. Fujita K, Murakami Y, Hayashi S. A macromolecular inhibitor of the antizyme to ornithine decarboxylase. The Biochemical Journal. 1982;204(3):647-652
  18. 18. Kitani T, Fujisawa H. Purification and characterization of antizyme inhibitor of ornithine decarboxylase from rat liver. Biochimica et Biophysica Acta. 1989;991(1):44-49
  19. 19. Ivanov IP, Gesteland RF, Atkins JF. Survey and summary: Antizyme expression: A subversion of triplet decoding, which is remarkably conserved by evolution, is a sensor for an autoregulatory circuit. Nucleic Acids Research. 2000;28(17):3185-3196
  20. 20. Ivanov IP, Gesteland RF, Atkins JF. A second mammalian antizyme: Conservation of programmed ribosomal frameshifting. Genomics. 1998;52(2):119-129
  21. 21. Ivanov IP, Rohrwasser A, Terreros DA, Gesteland RF, Atkins JF. Discovery of a spermatogenesis stage-specific ornithine decarboxylase antizyme: Antizyme 3. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(9):4808-4813
  22. 22. Tosaka Y, Tanaka H, Yano Y, Masai K, Nozaki M, Yomogida K, et al. Identification and characterization of testis specific ornithine decarboxylase antizyme (OAZ-t) gene: Expression in haploid germ cells and polyamine-induced frameshifting. Genes to Cells: Devoted to Molecular & Cellular Mechanisms. 2000;5(4):265-276
  23. 23. Chen H, MacDonald A, Coffino P. Structural elements of antizymes 1 and 2 are required for proteasomal degradation of ornithine decarboxylase. The Journal of Biological Chemistry. 2002;277(48):45957-45961
  24. 24. Snapir Z, Keren-Paz A, Bercovich Z, Kahana C. Antizyme 3 inhibits polyamine uptake and ornithine decarboxylase (ODC) activity, but does not stimulate ODC degradation. The Biochemical Journal. 2009;419(1):99-103. 1 p following
  25. 25. Zhu C, Lang DW, Coffino P. Antizyme 2 is a negative regulator of ornithine decarboxylase and polyamine transport. The Journal of Biological Chemistry. 1999;274(37):26425-26430
  26. 26. Murai N, Murakami Y, Tajima A, Matsufuji S. Novel ubiquitin-independent nucleolar c-Myc degradation pathway mediated by antizyme 2. Scientific Reports. 2018;8(1):3005
  27. 27. Kajiwara K, Nagawawa H, Shimizu-Nishikawa S, Ookuri T, Kimura M, Sugaya E. Molecular characterization of seizure-related genes isolated by differential screening. Biochemical and Biophysical Research Communications. 1996;219(3):795-799
  28. 28. Murai N, Shimizu A, Murakami Y, Matsufuji S. Subcellular localization and phosphorylation of antizyme 2. Journal of Cellular Biochemistry. 2009;108(4):1012-1021
  29. 29. Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine & Growth Factor Reviews. 1998;9(1):49-61
  30. 30. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A. Bone morphogenetic proteins: A critical review. Cellular Signalling. 2011;23(4):609-620
  31. 31. Lin Y, Martin J, Gruendler C, Farley J, Meng X, Li BY, et al. A novel link between the proteasome pathway and the signal transduction pathway of the bone morphogenetic proteins (BMPs). BMC Cell Biology. 2002;3:15
  32. 32. Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M, et al. Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. The Journal of Biological Chemistry. 2004;279(40):41504-41511
  33. 33. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biology & Therapy. 2002;1(3):226-231
  34. 34. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes & Development. 1997;11(8):957-972
  35. 35. Liu YC, Lee CY, Lin CL, Chen HY, Liu GY, Hung HC. Multifaceted interactions and regulation between antizyme and its interacting proteins cyclin D1, ornithine decarboxylase and antizyme inhibitor. Oncotarget. 2015;6(27):23917-23929
  36. 36. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. The EMBO Journal. 1998;17(11):3052-3065
  37. 37. Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. British Journal of Cancer. 2001;84(6):824-831
  38. 38. Buschhorn HM, Klein RR, Chambers SM, Hardy MC, Green S, Bearss D, et al. Aurora-A over-expression in high-grade PIN lesions and prostate cancer. The Prostate. 2005;64(4):341-346
  39. 39. Littlepage LE, Ruderman JV. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes & Development. 2002;16(17):2274-2285
  40. 40. Taguchi S, Honda K, Sugiura K, Yamaguchi A, Furukawa K, Urano T. Degradation of human Aurora-A protein kinase is mediated by hCdh1. FEBS Letters. 2002;519(1-3):59-65
  41. 41. Lim SK, Gopalan G. Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A. Oncogene. 2007;26(46):6593-6603
  42. 42. Abrieu A, Magnaghi-Jaulin L, Kahana JA, Peter M, Castro A, Vigneron S, et al. Mps1 is a kinetochore-associated kinase essential for the vertebrate mitotic checkpoint. Cell. 2001;106(1):83-93
  43. 43. Stucke VM, Silljé HH, Arnaud L, Nigg EA. Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. The EMBO Journal. 2002;21(7):1723-1732
  44. 44. Kasbek C, Yang CH, Fisk HA. Mps1 as a link between centrosomes and genomic instability. Environmental and Molecular Mutagenesis. 2009;50(8):654-665
  45. 45. Kasbek C, Yang CH, Yusof AM, Chapman HM, Winey M, Fisk HA. Preventing the degradation of mps1 at centrosomes is sufficient to cause centrosome reduplication in human cells. Molecular Biology of the Cell. 2007;18(11):4457-4469
  46. 46. Kasbek C, Yang CH, Fisk HA. Antizyme restrains centrosome amplification by regulating the accumulation of Mps1 at centrosomes. Molecular Biology of the Cell. 2010;21(22):3878-3889
  47. 47. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nature Reviews. Cancer. 2002;2(8):605-615
  48. 48. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr. Chemosensitivity linked to p73 function. Cancer Cell. 2003;3(4):403-410
  49. 49. Lin KW, Nam SY, Toh WH, Dulloo I, Sabapathy K. Multiple stress signals induce p73beta accumulation. Neoplasia (New York, NY). 2004;6(5):546-557
  50. 50. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V. DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur. Cell Death and Differentiation. 2004;11(6):685-687
  51. 51. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH, et al. The ubiquitin-protein ligase Itch regulates p73 stability. The EMBO Journal. 2005;24(4):836-848
  52. 52. Dulloo I, Gopalan G, Melino G, Sabapathy K. The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(11):4902-4907
  53. 53. Ramos-Molina B, Lopez-Contreras AJ, Cremades A, Penafiel R. Differential expression of ornithine decarboxylase antizyme inhibitors and antizymes in rodent tissues and human cell lines. Amino Acids. 2012;42(2-3):539-547
  54. 54. Watson JA, Fang M, Lowenstein JM. Tricarballylate and hydroxycitrate: Substrate and inhibitor of ATP: Citrate oxaloacetate lyase. Archives of Biochemistry and Biophysics. 1969;135(1):209-217
  55. 55. Chypre M, Zaidi N, Smans K. ATP-citrate lyase: A mini-review. Biochemical and Biophysical Research Communications. 2012;422(1):1-4
  56. 56. Tajima A, Murai N, Murakami Y, Iwamoto T, Migita T, Matsufuji S. Polyamine regulating protein antizyme binds to ATP citrate lyase to accelerate acetyl-CoA production in cancer cells. Biochemical and Biophysical Research Communications. 2016
  57. 57. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nature Reviews. Cancer. 2008;8(12):976-990
  58. 58. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nature Reviews. Cancer. 2010;10(4):301-309
  59. 59. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(16):7804-7808
  60. 60. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. The EMBO Journal. 2004;23(10):2116-2125
  61. 61. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(24):9085-9090
  62. 62. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biology. 2004;6(4):308-318
  63. 63. Liu YC, Hsu DH, Huang CL, Liu YL, Liu GY, Hung HC. Determinants of the differential antizyme-binding affinity of ornithine decarboxylase. PLOS One. 2011;6(11):e26835
  64. 64. Bercovich Z, Snapir Z, Keren-Paz A, Kahana C. Antizyme affects cell proliferation and viability solely through regulating cellular polyamines. The Journal of Biological Chemistry. 2011;286(39):33778-33783

Written By

Noriyuki Murai

Submitted: 01 April 2020 Reviewed: 22 April 2020 Published: 04 June 2020